IVT and Solvo Announces Distribution Agreement For Solvo’s Products
News Oct 25, 2005
In Vitro Technologies, Inc. (IVT) and Solvo Biotechnologies Inc. have announced that they have formed a strategic partnership to distribute Solvo’s in vitro ABC Membrane Transporter Assay Product Line in the US and Canada.
Continuing with IVT’s commitment to bring an extensive line of solutions for drug discovery and development research, IVT and Solvo have collaborated to leverage IVT’s strength in the marketplace and Solvo’s innovative Membrane Transporter products.
“We are very excited about this partnership with Solvo and firmly believe that it will deliver additional value to pharmaceutical research customers in North America,” said Dr. Paul Silber, President and CEO of IVT.
“By making the products available from with in the United States, we are making the purchase process efficient and cost-effective coupled with increased ability to provide technical support.”
“By now, it is common knowledge among researchers that ABC transporters play a key role in the function of the blood-brain barrier (BBB), blood-CSF barrier, blood-testis barrier, intestinal epithelia (absorption), airway epithelia, liver epithelia and the kidney epithelia,” explained Gábor Heltovics, Solvo’s Business Development Director.
“Solvo’s leading in vitro assay systems are designed to detect interaction of test compounds with a wide array of ABC Transporter proteins found at these vital pharmacological barriers.”
“Our products are widely used for in vitro ADME/Tox, DMPK, oncology drug research and multi-drug resistant (MDR) modulating agent discovery.”
“We welcome the opportunity to work with In Vitro Technologies, Inc. as an ideal partner to further expand the usage of our products”.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019